OR WAIT null SECS
Quanticate Sets Out to Becomes a Major New Player in the Global CRO Market
QUANTICATE SETS OUT TO BECOME A MAJOR NEW PLAYER IN THE GLOBAL CRO MARKET
David Underwood, Chief Executive took advantage of the DIA conference in Boston to launch the Quanticate brand in the US market.
Quanticate is an integration of the strengths and capabilities of two longstanding and respected service providers to the pharmaceutical industry in Statwood and Oxford Pharmaceutical Sciences. After 5 years of close collaboration, the two companies have successfully completed a formal integration creating a single entity called Quanticate.
The company set up its first US operation in Boston in July 2007 in response to demand from its US based customers and the launch of Quanticate represents the first step in major expansion plans to expand the company’s capabilities and presence in the North American market.
With over 200 members of staff and nine offices on 3 continents, Quanticate already has the resources and capabilities of a global player and while providing the full range of CRO services has particular expertise in biometrics and medical writing.
The company has its own world class EDC / paper solution called ClinNav™ and is well known for its flexible approach to data collection and management and its ability to integrate with its customers own technology environments.
David Underwood commented: “The launch of Quanticate is a truly exciting moment in our history and provides the ideal springboard for our continued expansion into global and full service clinical research solutions and into the US market. We expect to add further capabilities over the coming months and Quanticate is a name and a company that we expect to grow rapidly in terms of its recognition as a leading player in our field.”